Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives - PubMed
3 hours ago
- #Elranatamab
- #BCMA
- #Multiple Myeloma
- Elranatamab is a humanized BCMA × CD3 bispecific antibody effective in treating relapsed and refractory multiple myeloma (RRMM).
- It demonstrates high response rates, durable disease control, and manageable toxicity, including low-grade cytokine release syndrome.
- Effective in patients previously exposed to BCMA-targeted therapies and feasible for high-risk populations like those with severe renal impairment.
- Uncertainties remain regarding optimal sequencing, long-term survival benefits, infection risk management, and resistance mechanisms.
- Elranatamab is a valuable addition to RRMM treatment, with ongoing studies needed to refine its use and identify benefiting patients.